Emory University

Cocrystal Pharma, Inc.

Rfs Pharma LLC

Hadasit Medical Research Services and Development Ltd.

Franck Amblard

Raymond F Schinazi

Steven J Coats

Longhu Zhou

Junxing Shi

Richard Anthony Whitaker

Hongwang Zhang

Tamara Rosario McBrayer

Christina Gavegnano

Shaoman Zhou

Ozkan Sari

Keivan Zandi

Benjamin D Kuiper

Hao Li

Eithan Galun

Ahmed Khalil

Hilla Giladi

Bryan D Cox

Leda Bassit

Bradley J Keusch

Ladislau Kovari

Sebastien Boucle

Peng Liu

Seema Mengshetti

Chofit Chai

Compounds, compositions and methods for modulating retinoic acid receptor-like orphan receptors (ROR) and associated diseases. Methods for treatment or prophylaxis of metabolic disorders, liver disorders or diseases, including NASH, immune disorders, central nervous system disorders, or cancer are disclosed.

Modulators of orphan nuclear receptors for NASH and other metabolic disorders

Compounds, compositions and methods for preventing, treating or curing a coronavirus, picornavirus, and/or hepeviridae virus infection in human subjects or other animal hosts. Specific viruses that can be treated include enteroviruses. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1 (OC43), and SARS-CoV-2. In another embodiment, the methods are used to treat a patient co-infected with two or more of these viruses, or a combination of one or more of these viruses and norovirus.

Peptidomimetics for the treatment of coronavirus and picorna virus infections

Nucleoside compounds, which in some embodiments include an alkynyl substituent at the 4'-position, compositions and methods for treating or preventing HIV and other viral infections, particularly where the virus is present in macrophages, microglia, and primary myeloid cells, and eliminating and/or treating infection in patients infected by these viruses, are disclosed.

Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents

The present invention is directed to compounds, compositions and methods for treating or preventing Zika virus. The compounds include pyrimidine and purine nucleosides and prodrugs thereof, including certain N-hydroxycytidine nucleoside derivatives, sulfasalazine, and various entry inhibitors.

Antiviral agents and nucleoside analogs for treatment of Zika virus

The present invention is directed to compounds, compositions and methods for preventing, treating or curing Norovirus infection in human subjects or other animal hosts.

Peptidomimetics for the treatment of Norovirus infection

The present invention is directed to compounds, compositions and methods for preventing, treating or curing Hepatitis B (HBV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment, prevention or eradication of HBV infection.

Elimination of hepatitis b virus with antiviral agents

Peptidomimetics for the treatment of coronavirus and picornavirus infections

Peptidomimetics for the treatment of norovirus infection

Elimination of hepatitis B virus with antiviral agents

The present invention is directed to compounds, compositions and methods for treating or preventing Flaviviridae family of viruses (including HCV, Yellow fever, Dengue, Chikungunya and West Nile virus), RSV, HEV, and influenza infection and cancer in human subjects or other animal hosts.

Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer

The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.

Potent and selective inhibitors of hepatitis C virus

The compounds are of the class of N4-hydroxycytidine nucleosides, modified monophosphate and phosphonates prodrugs analogs, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof, useful in treating HCV or Norovirus infections.

Pyrimidine nucleosides and their monophosphate prodrugs for the treatment of viral infections and cancer

Growing community of inventors

Tucker, GA, United States of America

Franck Amblard